Broker Meets Biotech 2018 Series

Brisbane | Perth | Adelaide


Presenting Companies



AdAlta Limited (ASX: 1AD) - presenting in QLD session

AdAlta Limited is an ASX listed drug development company headquartered in Melbourne. The Company is focused on using its proprietary technology platform to generate i-bodies, a new class of protein therapeutics, with applications as therapeutic drugs to treat disease. AdAlta is developing its lead i-body candidate, AD-214, for the treatment of idiopathic pulmonary fibrosis (IPF) and other human fibrotic diseases, for which current therapies are sub-optimal and there is a high-unmet medical need. The Company also plans to continue further drug discovery and development directed towards other drug targets and diseases with its i-body technology platform.



Cynata Therapeutics Limited (ASX:CYP) - presenting in WA session

Cynata Therapeutics Limited (ASX:CYP) is a clinical stage stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™.The proprietary Cymerus technology addresses a critical shortcoming in existing methods of production of multi-donor derived mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve consistent, economic manufacture at commercial scale. Patient enrolment was recently completed in a Phase 1 clinical trial of the Company’s first product in graft-versus-host disease; initial results are very promising.  Cynata has a strategic partnership with Fujifilm, which is one of the Company’s larger shareholders.



Biotron Limited (Biotron, ASX:BIT) - presenting in WA session

Biotron Limited (Biotron, ASX:BIT) is a clinical stage Australian biotechnology. The company is developing new small molecule drugs to treat significant viral infections, including HIV-1, Hepatitis B and Hepatitis C viruses. Its lead drug BIT225 has proven clinical activity against HIV-1 and HCV, with 8 clinical trials completed. BIT225 has potential to eliminate one of the major HIV-1 viral reservoirs. The presence of virus, even in patients receiving the latest anti-HIV treatment, causes on-going medical issues. Eradication of HIV-1 is a current focus of scientists, clinicians and the pharmaceutical industry and is an area where BIT225 has potential. A pivotal hase 2 trial has been completed, with data due mid-2018. Biotron is currently focused on achieving a commercial outcome for its portfolio of antiviral programs.


Factor Therapeutics Ltd (ASX:FTT) - presenting in WA and SA sessions

Factor Therapeutics Ltd (ASX:FTT) is an Australian biotechnology company pursuing the development and commercialisation of advanced wound care therapeutics.  The Company’s lead program, VF001, is a targeted growth factor that is being developed to treat venous leg ulcers (VLUs). Chronic wounds, such as VLUs, are common, painful and debilitating – a silent epidemic.



Prescient Therapeutics (ASX: PTX) - presenting in QLD and WA sessions

Prescient Therapeutics (ASX: PTX) is a clinical stage oncology company developing targeted therapies that address specific mutations that drive cancer and contribute to resistance.

Prescient’s lead drug candidate PTX-200 inhibits an important tumor pathway known as Akt.  Its Phase 1b breast cancer trial demonstrated an efficacy signal that was double that expected of standard of care. This trial is now in Phase 2.  Trials in leukemia and ovarian cancer are also underway.

Prescient’s exciting compound PTX-100 is a first in class inhibitor of the highly sought-after Ras pathway, and will be the focus of a “basket” study that has transformed similar companies in the US.  



ResApp Health Limited (ASX: RAP) - presenting in QLD session

ResApp Health is a digital health company developing smartphone applications for the diagnosis and management of respiratory disease. ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional hardware. Clinical studies underway at leading hospitals in the US and Australia have demonstrated accurate diagnosis of pneumonia, asthma, bronchiolitis, croup, COPD and upper respiratory tract infections. ResApp has also obtained excellent results for screening of obstructive sleep apnoea in a proof-of-concept clinical study. Potential customers of ResApp’s products include healthcare providers in telehealth, emergency department, urgent care and primary care settings.



Rhinomed Limited (ASX:RNO) - presenting in QLD and WA sessions

Rhinomed Limited (ASX:RNO) is a Melbourne based medical technology firm with a focus on nasal, respiratory and breathing management technologies. The company is developing and commercialising applications of its technology portfolio in the sport, sleep, cough/cold and allergy, and drug delivery markets. The company has two products in market (the Turbine for sports and exercise and Mute for snoring and better sleep). It's sleep product Mute is currently in over 13,000 retail stores globally. Rhinomed is seeking to become the entry point to the global sleep category across the retail, online and clinical channels.



Volpara Health Technologies Ltd (ASX:VHT) - presenting in QLD and SA sessions

Volpara Health Technologies Ltd (ASX:VHT) is a medical technology company whose AI imaging algorithms assist in the early detection of breast cancer. Cloud-based VolparaEnterprise enables breast imaging facilities’ technologists to track their own performance, setting the stage for improved compression and positioning of women during screening helping provide more personalised screening options, detect cancer earlier, improve patient comfort. The software is set to help US breast imaging centres meet FDA regulatory requirements.




Race Oncology (ASX:RAC) - presenting in SA session

Race Oncology is a specialty pharmaceutical company pursuing late stage drug assets overlooked by big pharma. Our first asset is a chemotherapy agent called Bisantrene, which was the subject of more than 40 phase II studies, before it was lost in a series of big pharma mergers during the 1990s. We intend to complete final clinical development and seek regulatory approval in the US for relapsed/refractory Acute Myeloid Leukemia (AML), while making the drug available to doctors and patients under a Named Patient Program in certain countries.




Imugene (ASX: IMU) - presenting in SA session

Imugene is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumors. Our unique platform technology seeks to harness the body’s immune system to develop antibodies against diseases, achieving a similar or better effect than antibody therapies made in an industrial facility. Our product pipeline includes multiple validated product candidates aimed at treating a variety of cancers in combination with standard of care chemotherapy and emerging immuno-therapies. We have assembled a world leading team of highly motivated experts with extensive and proven experience in developing new cancer drugs for global markets.





To express your interest to present your company please download and complete our booking form



2018 Broker Meets Biotech events supported by:


Adelaide Event Partner Brisbane Event Partner



Tweets by @AusBiotech